ABSTRACT: Trauma, surgery, and other inflammatory conditions can lead to debilitating joint contractures. Adjunct pharmacologic modalities may permit clinical prevention and treatment of recalcitrant joint contractures. We investigated the therapeutic potential of rosiglitazone by intra-articular delivery via oligo[poly(ethylene glycol)fumarate] (OPF) hydrogels in an established rabbit model of arthrofibrosis. OPF hydrogels loaded with rosiglitazone were characterized for drug elution properties upon soaking in minimum essential media (MEM) with 10% fetal bovine serum and measurements of drug concentrations via High Performance Liquid Chromatography (HPLC). Drug-loaded scaffolds were surgically implanted into 24 skeletally mature female New Zealand White rabbits that were divided into equal groups receiving OPF hydrogels loaded with rosiglitazone (1.67 mg), or vehicle control (10 ml DMSO). After 8 weeks of joint immobilization, rabbits were allowed unrestricted cage activity for 16 weeks. Contracture angles of rabbit limbs treated with rosiglitazone showed statistically significant improvements in flexion compared to control animals (mean angles, respectively, 64.4˚vs. 53.3˚, p < 0.03). At time of sacrifice (week 24), animals in the rosiglitazone group continued to exhibit less joint contracture than controls (119.0˚vs. 99.5˚, p ¼ 0.014). The intra-articular delivery of rosiglitazone using implanted OPF hydrogels decreases flexion contractures in a rabbit model of arthrofibrosis without causing adverse effects (e.g., gross inflammation or arthritis). Statement of Clinical Significance: Post-traumatic joint contractures are common and debilitating, with limited available treatment options. Pharmacologic interventions can potentially prevent and treat such contractures. This study is translational in that a commercially approved medication has been repurposed through a novel delivery device. ß
The pathogenesis of fibrosis has been extensively studied in many somatic tissues including skin, hepatic, lung, and heart, 1-5 but far less is known about arthrofibrosis that causes debilitating joint contractures. Joint fibrosis is due to surgery, trauma, and other medical conditions, and is associated with significant loss of motion. For example, a 50% loss in elbow motion translates into an 80% loss of function. 6 Challenges to the prevention and treatment of arthrofibrosis persist, because the primary causes of arthrofibrosis remain unclear and recurrent joint contractures occur in patients that resist treatment. Extensive physical therapy and/or surgical intervention can improve the range of joint motion in patients with arthrofibrosis, yet residual or recurrent stiffness is a major clinical problem that remains to be addressed. [7] [8] [9] [10] [11] [12] [13] [14] In an effort to find a clinical solution for arthrofibrosis, we have developed and validated a rabbit model of post-traumatic knee contracture. This rabbit model of arthrofibrosis displays severe joint stiffness by 8 weeks of immobilization and sustained joint contracture for at least 16 weeks after remobilization. 15 In this rabbit model of arthrofibrosis, joint stiffening is provoked by cortical window defects, cruciate ligament sectioning, and hyperextension injuries of capsular structures. The resulting joint contractures mimic those in patients with significant joint trauma, and render the rabbit model of arthrofibrosis suitable for in-depth studies of arthrofibrosis mitigation strategies, including those involving pharmacologic agents. 16, 17 Activation of fibroblasts by Transforming Growth Factor-b proteins (i.e., TGF-b1, TGF-b2, or TGF-b3; encoded by, respectively, TGFB1, TGFB2, and TGFB3 genes) produces fibrotic connective tissues that are central to the development of traumatic joint stiffness. Sustained TGF-b stimulation leads to prolonged and increased extracellular matrix (ECM) synthesis and deposition by fibroblasts. 16, [18] [19] [20] Prior studies by our group and others have characterized inhibitors of TGF-b activated fibroblast differentiation in vitro. 21, 22 Specifically, anti-fibrogenic effects relevant to joint contracture releases have been observed upon treatment with rosiglitazone, which is a thiazolidinedione (TZD) that acts as an agonist for transcription factor peroxisome proliferator-activated receptor gamma (PPAR-g, PPARG). 1, [23] [24] [25] [26] [27] [28] [29] Rosiglitazone has clinically approved applications for the treatment of diabetes mellitus and in this context acts by increasing the expression of genes that promote lipid storage and decreasing expression of inflammatory chemokines (e.g., interleukin-6, IL6) in human adipocytes. 30 A large meta-analysis evaluating the safety profile of rosiglitazone in over 42,000 patients demonstrated no increase of all-cause or cardiovascular mortality upon drug application. 31 To deliver this promising therapeutic reagent into the intra-articular space, we utilized fumarate cross-linked polyethylene glycol-based hydrogels (oligo[poly(ethylene glycol)fumarate]; OPF), because fumarate cross-links improve the mechanical properties of this biopolymer scaffold and OPF have been shown to degrade safely and effectively in vivo. 32 Prior to implantation we characterized the drug elution profile of OPF hydrogels loaded with rosiglitazone to demonstrate that this drug may be released in high concentrations over a prolonged period.
The goal of this study was to investigate the safety and efficacy of rosiglitazone in mitigating joint arthrofibrosis in three ways. First, we performed in vitro cytotoxicity experimentation in human fibroblast cells to determine rosiglitazone dosing. Second, we assessed rosiglitazone elution from OPF scaffolds. Third, we performed in vivo biomechanical testing of the rabbit model of arthrofibrosis upon intra-articular implantation of OPF scaffolds. The main finding of our study is that intra-articular delivery of rosiglitazone using OPF scaffolds is safe and improves the contracture angles of rabbits with arthrofibrosis.
MATERIALS AND METHODS
In Vitro Cytotoxicity of Fibroblasts and Real Time PCR Analysis Human fibroblasts were purchased from Asterand (Detroit, MI). A total of 10 5 fibroblasts were counted and harvested onto 30 mm tissue culture dishes in minimum essential media (MEM) with 10% fetal bovine serum (FBS) at 37˚C in a 5% CO 2 incubator. Rosiglitazone (Sigma-Aldrich, Milwaukee, WI) was dissolved into dimethyl sulfoxide (DMSO) (SigmaAldrich). One hour prior to drug exposure, fibroblasts were stimulated with TGF-b1 (10 ng/ml; R&D Systems, Minneapolis, MN) to promote conversion into myofibroblasts and activate ECM synthesis. Rosiglitazone was added at various concentrations (10, 20 , and 50 mM) to the myofibroblasts and DMSO vehicle was used as the control.
After 24 h, total RNA was extracted from the cells via RNeasy kit (Quiagen, Valencia, CA). Isolated RNA was converted into cDNA using Superscript II following the instructions of the manufacturer (Invitrogen, Carlsbad, CA). Duplicate quantitative RT-PCR was performed for triplicate RNA samples using a QuantiTect SYBR Green RT-PCR kit (Quiagen) and a Detection System (Cepheid, CA). Quantitative RT-PCR was performed in a total reaction volume of 25 ml containing 12.5 ml of Quanti-Tect SYBR Green RT-PCR master mix, 3 ml of cDNA template and 0.2 mmol of each target-specific primer designed to amplify a part of each gene. Primers specific for COL1A and a-smooth muscle actin (aSMA/ACTA2) were used. After PCR, a melting curve analysis was performed to demonstrate the specificity of each PCR product as a single peak. A control reaction containing all the components except for the template was included in all experiments. COL1A and aSMA/ACTA2 gene expression levels were normalized to expression levels of rabbit b-actin (ACTB). Levels of COL1A1 and aSMA/ACTA2 mRNAs levels were expressed as fold response to rosiglitazone in TGF-b treated cells.
Rosiglitazone Elution Preparation
To verify the ability of the OPF hydrogels to absorb and release rosiglitazone, the hydrogels were loaded with 10 ml DMSO with or without 1.67 mg rosiglitazone. Drug elution properties were characterized by soaking the scaffolds in 1 ml of MEM with 10% FBS at 37˚C in a 5% CO 2 incubator. Each scaffold (five scaffolds per drug) was transferred into a new Eppendorf tube with fresh media over a span of 14 days. The media was utilized to measure the drug concentration via HPLC methods described in the next paragraph.
Preparation of Rosiglitazone Calibration Standards and Samples
Rosiglitazone stock solutions (1 mM) were prepared in DMSO. A serial dilution calibration curve was prepared in media with final concentrations of 10, 5, 1, 0.5, 0.1, and 0.05 mM. A 300 ml of acetonitrile was added to 100 ml of each dilution to precipitate the proteins. Prepared standard samples were vortexed for 3 min and centrifuged at 17,000g for 15 min. A 300 ml of the supernatant was transferred to an autosampler vial for LC-MS/MS analysis. A 1 ml of the 140 sponge samples was diluted into 99 ml of media. The proteins were precipitated with 300 ml acetonitrile, vortexed, and centrifuged as noted above. The supernatant was transferred to an autosampler vial and analyzed by LC-MS/MS.
Instrumentation Method
The LC-MS/MS system consisted of a Thermo Accela Classic HPLC pump and PAL autosampler integrated to a Quantum Ultra triple quadrupole mass spectrometer. The analytical column used was a Thermo Hypersil Gold; 50 Â 2.1 mm ID; particle size 1.9 m. Mobile phases were water with 0.1% formic acid in pump A and acetonitrile with 0.1% formic acid in pump B. The flow rate was 0.25 ml/min and the column was heated to 45˚C. Separation was achieved using a gradient of 25-90%B over 10 min. Full loop injections of 5 ml were used for all samples and standards. Mass spectra were collected in positive electrospray ionization mode. Rosiglitazone standards were infused directly into the source and optimized for transition states, collision energies, and tune parameters. The transitions (precursor to product) monitored were 382.05!303.2 (CE 32V) and 382.05!362.1 (CE 33V) for rosiglitazone. The six-point calibration curve was constructed by plotting the area under the curves of the rosiglitazone concentrations. Thermo Xcaliber software (version 2.07 SP1) was used to calculate the regression parameters of slope, intercept, and correlation coefficient by weight (1/x) regression.
In Vivo Analysis of Intra-Articular OPF Scaffold Implantation Using the Rabbit Model of Arthrofibrosis Following institutional approval (IACUC; Mayo Clinic, Rochester, MN), 24 female skeletally mature New Zealand White (NZW) rabbits weighing between 3 and 4 kg were selected for the study utilizing a previously published rabbit model of joint contracture. 15 Rabbits were randomly divided into two study groups (rosiglitazone group and control group; n ¼ 12 each). All rabbits had their right knee operated as described previously. 15 Briefly, the index surgery entailed 3-mm drill defects created on the non-cartilaginous parts of the medial and lateral femoral condyles, complete transection of the cruciate ligaments, followed by hyperextension of the joint to À45˚disrupting the posterior capsule. The joint was then immobilized in maximum flexion with a 1.6 mm Kirschner wire (K-wire) for 8 weeks while the rabbits were allowed 2950 ARSOY ET AL.
free-cage activity (0.19 m 3 ). At the time of surgery, one OPF scaffold (1 Â 1 Â 0.5 cm) was implanted into the supra-patellar pouch by direct visualization. The OPF scaffolds for each rabbit knee were loaded with DMSO (vehicle) and drug (rosiglitazone) under sterile conditions and stored at room temperature overnight prior to implantation. Most hydrogels remained non-dissolved in the knee joints, and there was no visual evidence of either gross inflammation or fibrous adhesions at the time of sacrifice.
The experimental group of 12 rabbits received the OPF scaffold that was loaded with rosiglitazone (1.67 mg), while the control group received OPF scaffold with vehicle alone (10 ml DMSO). The OPF scaffold materials were procured from the Mayo Clinic Tissue Engineering and Biomaterials Laboratory (Rochester, MN) and produced as previously described. 33, 34 After 8 weeks of immobilization and free-cage activity, a second surgery to remove the K-wire was performed. The joint contracture angle was measured under general anesthesia with a custom-made device (Mayo Clinic) allowing calculation and evaluation of the flexion contracture angle without having to sacrifice the animal (Fig. 1A and B) . Briefly, the femur was fixed to the device with the animal in supine position, and the ankle was pulled perpendicular to the tibia at 20 N Á cm. Fluoroscopic imaging was obtained for all operative limbs after K-wire removal. The angle formed by two lines was used to obtain flexion contracture angles of the operative limb (line 1 went through the center of the femoral canal and center of the femoral condyle; line 2 went through the center of the tibial canal and center of the tibial plateau). After K-wire removal, rabbits resumed free cage activity (0.19 m 3 ) for an additional 16 weeks before being sacrificed. Veterinarians were available for daily monitoring of all animals.
After 16 weeks of remobilization, all rabbits were sacrificed under anesthesia, and the operative limb was disarticulated. Skin, muscles, and tendons were removed except on the tibial tubercle up to 20 mm proximal to the knee joint. Tibias and femurs were cut 7 cm from the joint line. The joint contracture angle was immediately evaluated using the custom-made device and previously established protocols. 15 In short, standardized weights were used to calibrate the device, and the center of rotation of the joint was placed to the center of the torque cell as confirmed by fluoroscopic images. Intramedullary rods into both the femur and tibia secured this configuration. The rods were attached to the torque cell to apply an extension torque through a pulley at a rate of 1˚per second. The contracture angle at a torque of 20 N Á cm was considered adequate in concordance with previous descriptions of this system (Fig. 1C) . 15 Biomechanical results were documented as mean AE standard deviation. A two-sample t-test was used for statistical analysis with a significance value of p < 0.05. The analysis was conducted using SAS v.9.2 (SAS Institute, Inc., Cary, NC).
RESULTS

In Vitro Fibroblast Cytotoxicity and Real Time PCR Analysis
We evaluated the cell viability via XTT assay at various concentrations. Rosiglitazone concentrations up to 60 mM were non-toxic. To determine whether rosiglitazone has an anti-fibrogenic potential, we examined the effect of this drug on human fibroblast stimulated with TGF-b. Rosiglitazone suppressed expression of COL1A ( Fig. 2A) and aSMA/ACTA2 (Fig. 2B ) at higher concentrations, but the DMSO control group did not suppress TGF-b activation. These statistically significant results (p < 0.05) indicate that rosiglitazone inhibits the ECM synthesis of myofibroblasts at least in part at the level of mRNA expression.
Rosiglitazone OPF-Scaffold Elution Profile
In vitro drug elution analysis was conducted to quantify the duration of optimal drug delivery by OPF hydrogels. Rosiglitazone analysis revealed a concentration of approximately 200 mM in the first day, and decreased to approximately 50% its initial value by day 7, where the OPF hydrogel continued to show sustained delivery of rosiglitazone concentrations over a 14-day period (Fig. 3) . Results for both drugs were considered adequate to continue evaluation of the drug efficacy in an animal model. 
ROSIGLITAZONE-LOADED HYDROGELS IN A RABBIT MODEL OF ARTHROFIBROSIS
In Vivo Analysis of Intra-Articular OPF Scaffold Implantation Using the Rabbit Model of Arthrofibrosis Local rosiglitazone delivery via OPF hydrogel in the rabbit model of arthrofibrosis reduced joint contracture after 8 weeks of immobilization. All rabbits regained their pre-surgical weight by postoperative day 2. One rabbit in the control group was excluded due to iatrogenic injuries sustained during the initial surgery that led to severe knee joint damage. After 8 weeks of immobilization and removal of the K-wire, animals in the rosiglitazone group showed statistically significant improvements in limb flexion contracture angles compared to animals in the control group (64.4˚vs. 53.3˚, p ¼ 0.009) (Fig. 4A) . These results suggest that rosiglitazone may have short-term efficacy in early inflammatory stages of arthrofibrosis.
Local delivery of rosiglitazone showed less joint contracture after an additional 16 weeks of remobilization without gross damage to the joint. At the time of sacrifice (week 24) the rosiglitazone group showed additional suppression of joint contracture (119˚vs. 99.5˚, p ¼ 0.014) (Fig. 4B) . No macroscopic joint damage was observed in either group. Hence, rosiglitazone delivery in OPF sponges may have persistent beneficial effects in suppressing arthrofibrosis in the rabbit contracture model.
DISCUSSION
Arthrofibrosis remains a major clinical challenge, because there are no treatment options that delay disease progression, relieve the onset of symptoms, or prevent the recurrence of joint contracture. Thus, the present investigations are translationally focused on understanding the biological causes of joint contrac- ture formation and subsequent mechanism-based treatment with pharmaceutical agents. The main goal of our study was to evaluate early drug-based intervention in arthrofibrosis formation by inhibition of the acute, inflammatory phase (first 4-6 week after initial injury) to avoid or mitigate initiation of a chronic phase with persistent scar presence. Because rosiglitazone has demonstrated anti-fibrogenic properties that may attenuate joint contracture, 1, 23, [25] [26] [27] [28] [29] we tested whether the intra-articular administration of rosiglitazone could alleviate joint contracture in a rabbit model of arthrofibrosis. While this compound can be administered systemically, a critical element to this study was the enhanced safety and efficacy of rosiglitazone delivery directly into the joint space using OPF hydrogels. 32 In our study, we have shown that OPF hydrogels permit absorption and release of rosiglitazone, as well as permit targeted scaffold-based delivery of the drug in the intra-articular space.
Part of the healing process of damaged tissue involves controlled activation of fibroblasts. 35, 36 However, when fibroblasts activate in excess, the detrimental tissue deformities that are characteristic of arthrofibrosis impede beneficial tissue restoration. Our previously established rabbit model of arthrofibrosis reliably simulates arthrofibrosis as it is seen in the clinical setting. [15] [16] [17] [18] [19] Histologic analysis by Abdel et al. 19 revealed high numbers of myofibroblasts in the posterior capsule tissue during the early stages of posttraumatic injury. The hallmark of severe contracture formation in the setting of capsular damage is excessive myofibroblast activation and increased extracellular matrix synthesis by TGF-b, which has also been demonstrated in other tissue types. 20, 25 Thus, inhibition of fibroblast differentiation into myofibroblasts and concurrent ECM synthesis are considered reasonable targets for pharmacologic intervention. Rosiglitazone, a PPAR-g agonist, has been shown to decrease scar formation in vitro and in vivo, but limited data exists regarding its response on synovial tissue and cellular mechanisms. 1, 23, 26, 27, 37 From a technical perspective, OPF hydrogels decompose slowly over time and most rabbit knees showed residual scaffold material at the time of sacrifice. Yet, OPF has favorable biocompatibility and there was no evidence of gross inflammation or damage to surrounding tissues. Some hydrogels showed cellular encapsulation and further investigation of hydrogels might lead to delivery scaffolds with a more favorable, intra-articular degradation profile. [38] [39] [40] Although no macroscopic tissue damage was observed in this study, future in-depth histologic analyses of the cartilage and surrounding tissues exposed to high concentrations of each drug would further solidify the safety profile of local drug delivery strategies in articulating joints. A limitation of our study is that we do not know whether we have effectively prevented either drug from entering blood circulation. However, hydrogel-based local delivery in the joint is expected to confine drug release and minimize systemic side effects common to PPAR-g, such as nausea, peripheral edema, weight gain, headache, dizziness, upper respiratory infection, back pain, and diarrhea. 41 Our study pioneers the intra-articular delivery of rosiglitazone via OPF scaffolds and our results indicate that this strategy alleviates joint contracture formation in this rabbit model of arthrofibrosis.
Implantation of OPF scaffolds with or without rosiglitazone was performed at the time of index surgery. In vivo results after 8 weeks of immobilization showed a significantly improved contracture angle in animals that received rosiglitazone compared to control animals. Operated limbs immobilized with K-wires did not rehabilitate within the first 8 weeks. Therefore, the difference of contracture severity observed between groups is directly attributable to the drug effects. Positive biological effects of the drug were still noticeable 24 weeks after index surgery and initial OPF scaffold implantation. Specifically, the 
ROSIGLITAZONE-LOADED HYDROGELS IN A RABBIT MODEL OF ARTHROFIBROSIS
rosiglitazone group continued to experience a less severe contracture formation that was statistically significant when compared to the control group. Importantly, we did not observe a delay in wound healing in either of the groups throughout the study period. Collectively, our results support the conclusion that local administration of rosiglitazone is beneficial during the early stages of arthrofibrogenesis, is safe with regard to extra-articular wound healing, and demonstrates potentially anti-fibrotic effects during the rehabilitation phases of our rabbit model of arthrofibrosis.
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